Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1357

2.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
3.

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.

Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.

Pediatr Infect Dis J. 2010 Jun;29(6):e35-46. doi: 10.1097/INF.0b013e3181daf921.

PMID:
20375709
4.

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L.

J Infect Dis. 2010 Jun 1;201(11):1644-53. doi: 10.1086/652701.

5.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

6.

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillard P, Jilg W.

Vaccine. 2009 Oct 23;27(45):6284-90.

PMID:
19856521
7.

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand.

Vaccine. 2009 Dec 9;27(52):7428-35. doi: 10.1016/j.vaccine.2009.07.102. Epub 2009 Aug 13.

PMID:
19683087
8.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.

J Infect Dis. 2008 Sep 1;198(5):642-9. doi: 10.1086/590913.

9.

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

Leroux-Roels G.

Expert Opin Biol Ther. 2009 Aug;9(8):1057-71. doi: 10.1517/14712590903066695. Review.

PMID:
19555313
10.

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.

Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, Dramé M, Roman FP.

BMC Infect Dis. 2010 Nov 25;10:338. doi: 10.1186/1471-2334-10-338.

11.
12.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
13.

Current status and progress of prepandemic and pandemic influenza vaccine development.

Leroux-Roels I, Leroux-Roels G.

Expert Rev Vaccines. 2009 Apr;8(4):401-23. doi: 10.1586/erv.09.15. Review.

PMID:
19348557
14.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
15.

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.

Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G.

PLoS One. 2008 Feb 27;3(2):e1665. doi: 10.1371/journal.pone.0001665.

16.

A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Plosker GL.

Drugs. 2012 Jul 30;72(11):1543-57. doi: 10.2165/11209650-000000000-00000. Review.

PMID:
22788239
18.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G.

Lancet. 2007 Aug 18;370(9587):580-9.

PMID:
17707753
19.

Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults.

Yang PC, Yu CJ, Chang SC, Hsieh SM, Drame M, Walravens K, Roman F, Gillard P.

J Formos Med Assoc. 2012 Jun;111(6):333-9. doi: 10.1016/j.jfma.2011.02.006. Epub 2012 Apr 20.

20.

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.

Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.

Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12.

PMID:
22080174
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk